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Abstract
Canine leishmaniasis (CanL) is a disease caused by Leishmania infantum. Serological methods are the most 
common diagnostic techniques used for the diagnosis of the CanL. The objective of our study was to estimate the 
sensitivity and specificity of one in-house ELISA kit (ELISA UNIZAR) and three commercially available serological 
tests (MEGACOR Diagnostik GmbH) including an immunochromatographic rapid test (FASTest LEISH®), an 
immunofluorescent antibody test (MegaFLUO LEISH®) and an enzyme-linked immunosorbent assay (MegaELISA 
LEISH®), using latent class models in a Bayesian analysis. Two hundred fifteen serum samples were included. The 
highest sensitivity was achieved for FASTest LEISH® (99.38%), ELISA UNIZAR (99.37%), MegaFLUO LEISH® (99.36%) 
followed by MegaELISA LEISH® (98.49%). The best specificity was obtained by FASTest LEISH® (98.43%), followed 
by ELISA UNIZAR (97.50%), whilst MegaFLUO LEISH® and MegaELISA LEISH® obtained the lower specificity (91.94% 
and 91.93%, respectively). The results of present study indicate that the immunochromatographic rapid test 
evaluated FASTest LEISH® show similar levels of sensitivity and specificity to the quantitative commercial tests. 
Among quantitative serological tests, sensitivity and specificity were similar considering ELISA or IFAT techniques.
Keywords: Bayesian analysis, canine leishmaniasis, diagnostic techniques and procedures, gold standard, 
immunoglobulins.
Resumo
A leishmaniose canina (Lcan) é uma doença causada pela Leishmania infantum. Os métodos sorológicos são as 
técnicas diagnósticas mais utilizadas para o diagnóstico da leishmaniose canina. O objetivo do nosso estudo foi 
estimar a sensibilidade e a especificidade de um kit ELISA interno (ELISA UNIZAR) e de três testes sorológicos 
disponíveis comercialmente, feitos pelo mesmo fabricante (MEGACOR Diagnostik GmbH), incluindo um teste rápido 
imunocromatográfico (FASTest LEISH®), um teste de anticorpos imunofluorescentes (Megafluo LEISH®) e um ensaio 
de imunoabsorção enzimática (Megaelisa LEISH®), utilizando-se modelos de classe latentes numa análise bayesiana. 
Foram incluídas duzentas e quinze amostras de soro. A maior sensibilidade foi alcançada para Fastest LEISH® 
(99,38%), ELISA UNIZAR (99,37%), Megafluo LEISH® (99,36%) seguida por Megaelisa LEISH® (98,49%). A melhor 
especificidade foi obtida por FASTest LEISH® (98,43%), seguida por ELISA UNIZAR (97,50%), enquanto Megafluo 
LEISH® e Megaelisa LEISH® obtiveram a menor especificidade (91,94% e 91,93%, respectivamente). Os resultados 
do presente estudo indicam que o teste rápido imunocromatográfico, avaliado por FASTest LEISH® mostra níveis 
similares de sensibilidade e especificidade aos testes comerciais quantitativos incluídos. Entre os testes sorológicos 
quantitativos, a sensibilidade e a especificidade foram semelhantes, considerando-se as técnicas de ELISA ou IFI.
Palavras-chave: Análise bayesiana, leishmaniose canina, técnicas e procedimentos diagnósticos, padrão ouro, 
imunoglobulinas.
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Introduction
CanL is a vector-borne disease caused by Leishmania infantum, which dogs are considered the main domestic 
reservoir for human infection (Dantas-Torres, 2007). This infection is transmitted by the bite of infected female 
sand flies from the genera Phlebotomus in the Old World or Lutzomyia in the New World (Moreno & Alvar, 2002). 
In the Mediterranean basin, an estimation of 2.5 million dogs are infected by the parasite including subclinically 
infected dogs and sick dogs exhibiting clinical signs and/or clinicopathological abnormalities (Solano-Gallego et al., 
2009). Cases of subclinical infections, defined as a situation in which Leishmania infection is confirmed but clinical 
signs and/or clinicopathological abnormalities are not present have been documented in all areas where CanL is 
endemic. It is no longer believed that absolutely every infected dog will inevitably develop clinical leishmaniasis 
(Solano-Gallego et al., 2009). In fact, a small proportion (prevalence of the disease ranges between 3 and 10%) of 
the dogs infected with L. infantum in endemic regions will develop the disease following infection (Baneth et al., 
2008). The evolution of this chronic infection depends on the cell-mediated immune response from the host against 
the parasite, cellular protective immunity is associated with activation of the macrophages by different cytokines, 
particularly interferon-gamma, tumor necrosis factor-alpha and interleukin-2. By contrast, disease susceptibility, by 
releasing a mixed T helper (Th1 and Th2) lymphocyte cytokines, tend to promote non-protective antibody formation 
and correlate with a diminution or absent cell-mediated immunity (Hosein et al., 2017). In this sense, the number 
of circulating CD4+ cells and the CD4+/CD8+ ratio drop during the disease (Esch et al., 2013). In the case of CD8+, 
these T cells are responsible for lysis of the macrophages infected with L. infantum and their activation increases 
the synthesis of INF-γ and TNF-α (Barbiéri, 2006).
Different techniques to confirm L. infantum infection are available including parasitological methods with the 
direct identification and observation of the parasite such as cytology, histology, specific immunohistochemistry 
and the parasite culture; molecular methods to detect parasitic nucleic acids (DNA and RNA) by polymerase 
chain reaction (PCR) such as conventional PCR, nested PCR and quantitative PCR; and serological methods based 
on detecting specific antibodies response against L. infantum (Maia & Campino, 2018). Serology is the preferred 
diagnostic method for CanL considering information provided by the World Organisation for Animal Health (OIE, 
2016). Among serological methods, enzyme-linked immunosorbent assay (ELISA), indirect immunofluorescence 
antibody test (IFAT), and the immunochromatographic rapid test (ICT) represent the most frequent methods used 
for the detection of infection in dogs (Maia & Campino, 2008; Bourdeau et al., 2014).
For L. infantum infection there is no perfect diagnosis but the diagnosis must be appropriate for each situation. 
The gold standard test does not necessarily have 100% sensitivity (Se) and 100% specificity (Sp) but it is the most 
sensitive and specific test for diagnosing that infectious agent. In absence of a reference test, the Latent Class 
Analysis (LCA) allows the estimation of sensitivity and specificity of two or more tests without assuming the 
true antibody status of the population under study, avoiding the bias connected to the use of an imperfect test 
(Branscum et al., 2005). The aim of this study was the statistically evaluation of the Se and Sp of one in-house ELISA 
test in comparison with three different commercial serologic tests in two groups of canine serum samples, one 
from non-endemic areas, the other from endemic areas, assuming significant different epidemiological conditions 
and seroprevalences between the two groups by a latent class models in a Bayesian analysis.
Material and Methods
Study population and serum samples
A total of 215 serum samples from dogs admitted to the Veterinary Teaching Hospital of the University of 
Zaragoza (Spain) and from three different clinics from United Kingdom were used in this study. Serum samples 
were collected during the period from January 2017 to December 2018 and conserved at –25 °C until analyzed.
With the aim to evaluate the performances of the tests by means of Bayesian analysis, samples were stratified 
into two populations with different levels of prevalence: canine sera from a non-endemic area (group 1) and from 
an endemic area (group 2).
One hundred and ninety-five serum samples (group 2) came from The Ebro´s Valley, a Spanish region where 
CanL is endemic, and the remaining serum samples (group 1) were residual samples taken from dogs during a 
routine annual health check-up in the United Kingdom, a non-endemic area. Within group 2, each dog was classified 
in different subgroups (non-infected dogs, healthy seronegative dogs, infected seropositive dogs, clinically sick dogs 
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and finally dogs with serological positive result to other pathogens) according to the clinical information sent with the 
sample to the laboratory for diagnostic purpose. The subgroups were not considered for the statistical evaluation.
Serum samples selection have reflected different clinical settings in veterinary practice from diagnosis of 
L. infantum infection in healthy dogs to clinically sick dogs, based on clinical evaluation, routine red blood cell count, 
clinical chemistry, urinalysis and serum protein electrophoresis. The serology status was also routinely recorded 
by means of an in-house ELISA (Solano-Gallego et al., 2009), but this test had the only goal to assure the selection 
of a heterogeneous population and did not influence the statistical analysis.
In the case of dogs with serological positive result to other pathogens (cross-reaction group), serology was 
used together with a molecular test to detect L. infantum infection performed in a private laboratory. None of the 
samples used in the study came from dogs previously vaccinated with any of the two vaccines available in Spain 
to prevent CanL (Solano-Gallego et al., 2017).
Clinical and epidemiological data were considered for the selection and samples were collected for the sole 
intention of determining a diagnosis. Ethical approval was not needed, but owners were requested to sign an 
informed consent. The study was reported to the Bioethical Committee of the University of Zaragoza and conducted 
in accordance with the European (2010/63/UE) and national (RD1201/2005) directives on animal experimentation. 
This study did not require official or institutional ethical approval.
Non-endemic canine sera (group 1)
Twenty serum samples obtained from The United Kingdom were included. These dogs had never traveled to 
an endemic area and they had neither clinical signs nor laboratory abnormalities detected by routine red blood 
cell count, clinical chemistry, urinalysis and a serum protein electrophoresis.
Endemic canine sera (group 2)
A total of 195 sera were collected from dogs living in a leishmaniasis endemic area. To obtain a heterogeneous 
group of samples, some subgroups were considered: clinically-ill infected dogs, dogs infected by some other 
pathogens and seemingly healthy dogs that resulted seropositive or seronegative. The heterogeneity was based 
mainly on clinical evaluation and routine red blood cell count, clinical chemistry, urinalysis and serum protein 
electrophoresis. The serology status was also recorded, based on ELISA UNIZAR, but this classification did not have 
any influence on statistical evaluation, based only on the two groups 1 (non-endemic) and 2 (endemic).
Sixty-five serum samples from seronegative healthy dogs were obtained from the Veterinary Teaching Hospital 
- Zaragoza Veterinary Faculty (University of Zaragoza, Spain). These samples came from dogs that were taken to 
Hospital for a screening L. infantum infection purpose by quantitative serology. Clinical information showed absence 
of clinical signs during physical examination and no laboratory findings based on routine red blood cell count and 
clinical chemistry, serum protein electrophoresis and urine analysis.
Eighty-seven sera from naturally infected dogs presenting variable clinical manifestations and/or laboratory 
alterations were included. Among clinical signs detected compatible with CanL, these were lymphadenomegaly 
(n=74), skin lesions (n=65), weight loss (n=44), anorexia (n=36), ocular lesions (n=19), pale mucous membranes 
(n=15), lameness (n=10), fever (n=8), gastrointestinal signs (n=7), epistaxis (n=4) and muscular atrophy (n=2). 
On the other hand, laboratory abnormalities detected compatible with CanL were non-regenerative anemia (n=50), 
neutrophilia (n=9), lymphopenia (n=17), lymphocytosis (n=2), thrombocytopenia (n=11), renal azotemia (n=6), 
hyperproteinemia (n=52), dysproteinemia with hypoalbuminemia and inverted albumin: globulin ratio (n=63), 
serum protein electrophoresis alteration with hypergammaglobulinemia detected (n=70), proteinuria (n=29) and 
low urinary specific gravity (n=21). In all 87 sick dogs, L. infantum disease was confirmed by a positive serology to 
the ELISA UNIZAR with moderate (n=44) to high (n=43) concentrations of serum anti-Leishmania antibodies.
Twenty-four sera samples from dogs evaluated out of seasonal activity of sand flies with a low positive result to 
the ELISA UNIZAR were included. Clinical information showed absence of clinical signs during physical examination 
and no laboratory findings being classified as seropositive asymptomatic infected dogs. All dogs were negative to 
L. infantum infection using a quantitative PCR in blood.
Nineteen samples from dogs with a serological positive result to other pathogens were analyzed to evaluate 
any possible cross-reaction: Dirofilaria immitis (n=3, positive result to heartworm antigen test and modified Knott´s 
test), Neospora caninum (n=1, IFAT antibody titer of 1:100), Toxoplasma gondii (n=1, IFAT antibody titer of 1:80), 
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Rickettsia conorii (n=1, IFAT antibody titer of 1:20), Ehrlichia canis (n=1, IFAT antibody titer 1:40), Anaplasma platys 
(n=11, IFAT antibody titers ranging from 1:20 to 1:160) and finally a sample with two co-infections T. gondii (IFAT 
antibody titer of 1:160) and N. caninum (IFAT antibody titer of 1:100). All dogs were negative to L. infantum infection 
using a quantitative PCR in blood.
ELISA UNIZAR technique
Prior to performing the in-house ELISA, L. infantum antigen (strain MHOM/FR/78/LEM 75 belonging to L. infantum 
zimodeme MON-1) was obtained from parasite culture. For the ELISA UNIZAR, the crude antigen was adjusted to a 
concentration of 20 µg/mL with sterile phosphate buffered saline (PBS). Each plate was coated lightly with 100 µL/well 
of the 20 µg/mL antigen solution in 0.1 M carbonate/bicarbonate buffer (pH 9.6) and incubated overnight at 4 °C. 
Plates were then frozen and stored at –20 °C. One hundred microliters of dog serum, diluted 1:800 in phosphate 
buffered saline containing 0.05% Tween 20 (PBST) and 1% dry skimmed milk (PBST-M) were added to each well. 
The plates were incubated for 1 hour (h) at 37 °C in a moist chamber. After washing the plates three times with 
PBST for 3 minutes (min) followed by one wash with PBS for 1 min, 100 µL of Protein A conjugated to horseradish 
peroxidase (Thermo Fisher Scientific, Waltham, Massachusetts, USA) diluted 1:20000 in PBST-M was added to each 
well. The plates were incubated for 1 h at 37 °C in a moist chamber, followed by washes with PBST and PBS as 
described above. The substrate solution (ortho-phenylene-diamine) and stable peroxide substrate buffer (Thermo 
Fisher Scientific, Waltham, Massachusetts, USA) were added (100 µL per well) and developed for 20±5 min at room 
temperature in the dark. The reaction was terminated by adding 100 µL of 2.5 M H2SO4 to each well. Absorbance 
values were read at 492 nm (reference wavelength) in an automatic microELISA reader (ELISA Reader Labsystems 
Multiskan, Midland, Canada). Each plate included serum samples from a dog infected with L. infantum as confirmed 
by cytological examination as a positive control (calibrator) and serum samples from a healthy, non infected dog 
from the blood donor program as a negative control. The same calibrator serum sample was used for all assays, 
and the plates with an interassay variation greater than 10% were tested again. All samples and controls were 
analyzed in duplicate. The ELISA UNIZAR test was performed by a different researcher who had no knowledge 
of the rapid test, MegaFLUO LEISH® results and MegaELISA LEISH® results. The results were quantified as ELISA 
UNIT (EU) compared to a positive control serum sample used as a calibrator that was arbitrarily set to 100 EU. 
The cutoff value was set to 30 EU (mean+4 standard deviations of values from 70 apparently healthy dogs from a 
non-endemic area and that were not included in this study). Sera with an EU ≥ 200 were classified as high positive, 
with an EU ≥ 100 and < 200 as moderate positive, and with an EU > 30 and < 100 as low positive.
MegaFLUO LEISH®
The commercial IFAT test (MegaFLUO LEISH®, MEGACOR Diagnostik GmbH, Hörbranz, Austria) was performed 
as described in the instructions supplied with the test kit. Slides were examined under a fluorescence microscope 
(Leica DM750 RH; Leica Microsystems, Wetzlar, Germany) at 400× magnification and each well was compared 
to the fluorescence pattern observed in the positive and negative controls. All samples were examined by two 
different investigators. If discrepancies arose between results, a third observer participated. They were blinded to 
the results of the other serological tests.
MegaELISA LEISH®
The MegaELISA LEISH® test (MEGACOR Diagnostik GmbH, Hörbranz, Austria) is a quantitative indirect ELISA for 
the detection of anti-Leishmania infantum antibodies in the canine serum sample following instructions supplied 
with the test kit. The MegaELISA LEISH® test was performed by a different researcher without knowledge of the 
FASTest LEISH® test, the commercial MegaFLUO LEISH® and the ELISA UNIZAR results.
FASTest LEISH®
The ICT FASTest LEISH® test (MEGACOR Diagnostik GmbH, Hörbranz, Austria) is a qualitative serological test 
developed to detect canine antibodies against L. infantum based on immunochromatographic technology. All tests 
were stored at room temperature and were performed as described in the instructions supplied with the test kit. 
The examiner was blinded to the results of the quantitative serological tests.
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Statistical analysis
The Bayesian version (Branscum  et  al., 2005) of the LCA introduced by Hui & Walter (1980) was adopted 
for evaluate the accuracy of the four diagnostic tests, given the absence of a gold standard. A four tests - two 
populations model was built in order to estimate the Se and Sp of each diagnostic test. The model assumptions in 
the Hui & Walter (1980) version were (1) the different true prevalences of the two populations, (2) the Se and Sp 
of the tests were constant across subpopulations and (3) the tests were conditionally independent given the true 
infection status. Accounting for the first assumption, the model was run using endemic versus non-endemic area 
as subgroups. Additionally, different hypotheses about the dependence among tests were considered in the model 
building: (Toft et al., 2005) the conditional independence among all the tests, given the infection status (i.e. presence 
of antibodies against L. infantum), MOD 1 in Table 1; the conditional covariance between the ELISA UNIZAR and 
MegaELISA LEISH® tests and conditional independence among FASTest LEISH® and MegaFLUO LEISH® compared 
to ELISA UNIZAR and MegaELISA LEISH®, given the disease status (MOD 2). For both models, uninformative priors 
for the test accuracy and prevalences were used. All analyses were carried out using Markov chain Monte Carlo 
techniques and implemented in WinBUGS software. Posterior inferences were based on 50,000 iterations, after a 
burn-in of 10,000 iterations. Convergence was assessed by running multiple chains from dispersed starting values, 
observing autocorrelation among samplings and investigating the Brooks–Gelman–Rubin convergence statistic 
(Brooks & Gelman, 1998). The Deviance Information Criterion (DIC) was used as measure of the model fitting 
(smaller value is better). The median of the posterior distributions was used as an estimate for the parameters of 
interest; the 2.5 and 97.5% points were used as estimates of the 95% credibility intervals (95% Posterior credibility 
interval, 95% PCI). To test Se and Sp between tests, the Bayesian posterior probabilities (POPR) were calculated 
and used as hypothesis testing, like in traditional statistical methods.
Agreement between the results for all serological diagnostic techniques was determined using kappa statistic 
(measure of agreement between categorical variables), carried out with the SPSS software Version 22 (IBM Inc., 
Chicago, IL, USA). This parameter was determined as follows: no agreement (k < 0), slight agreement (0 < k <0.2), 
fair agreement (0.2 < k <0.4), moderate agreement (0.4 < k <0.6), substantial agreement (0.6 < k <0.8) and almost 
perfect agreement (k >0.8).
Table 1. Deviance Information Criterion (DIC), posterior median and 95% Posterior credibility interval (95% PCI) of population 
specific-prevalence (Prev), sensitivity (Se), specificity (Sp) and conditional covariances (covSe, covSp), assuming conditional 
independence among the four tests (MOD 1), conditional covariance between ELISA UNIZAR and MegaELISA LEISH® (MOD 2).
DIC






Prev endemic area 55.85 [48.87;62.70] 55.87 [48.84;62.75]
Prev non-endemic area 3.25 [0.12;16.12] 3.24 [0.12;16.08]
Se ELISA UNIZAR 99.37 [96.75;99.98] 99.31 [96.34;99.97]
Se MegaFLUO LEISH® 99.36 [96.67;99.98] 98.14 [94.50;99.70]
Se FASTest LEISH® 99.38 [96.73;99.98] 99.36 [96.67;99.98]
Se MegaELISA LEISH® 98.49 [95.06;99.79] 99.36 [96.69;99.98]
Sp ELISA UNIZAR 97.50 [93.38;99.42] 97.51 [93.33;99.42]
Sp MegaFLUO LEISH® 91.94 [85.79;96.06] 91.33 [85.05;95.67]
Sp FASTest LEISH® 98.43 [94.87;99.77] 98.45 [94.92;99.78]
Sp MegaELISA LEISH® 91.93 [85.84;96.06] 91.93 [85.79;96.10]
covSe 0.002 [0.000;0.020]
covSp 0.002 [-0.003;0.022]
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Results
The cross-tabulated counts of the raw test results are reported in the Table 2 for endemic area and non-endemic 
area including one of the 16 different test patterns (e.g. combination of results of the four serological tests detected 
in each group of dogs). 195 samples out of 215 (90.7%) showed concordant results for all tests included.
Table 2. Combination of results of the four serological tests detected in each group of dogs considering endemic and non-
endemic areas.
Serological technique Endemic area 
(n=195)
Non-endemic 
(n=20)ELISA UNIZAR MegaFLUO LEISH® FASTest LEISH® MegaELISA LEISH®
+ + + + 108 0
+ + + - 1 0
+ + - + 0 0
+ - + + 0 0
+ + - - 0 0
+ - - + 0 0
+ - - - 2 0
- + + + 0 0
- - + + 0 0
- + - + 0 0
- + - - 8 0
- + + - 0 0
- - - + 8 0
- - + - 1 0
- - - - 67 20
Abbreviations: - negative, + positive.
The posterior estimates (median and 95% PCI) are presented in Table 1. Looking at Deviance Information Criterion 
(DIC) (smaller is better), it seems that the model with conditional independence among all tests (MOD 1) would 
be the preferable one between the two models under evaluation. However, there were no detectable differences 
in posterior estimates from the two models. The results highlighted a very low prevalence for non-endemic area 
(3.25%) compared to the medium/high in the endemic area (55.85%). All tests showed high values of Se, near to 
100% for FASTest LEISH® (99.38%), ELISA UNIZAR (99.37%) and MegaFLUO LEISH® (99.36%), followed by MegaELISA 
LEISH® (98.49%). With regard to the Sp, FASTest LEISH® (98.43%) and ELISA UNIZAR (97.50%) showed significantly 
better performances (POPR < 0.05) compared to MegaFLUO LEISH® (91.94%) and MegaELISA LEISH® (91.93%).
Agreement between tests was almost perfect (k>0.80) for the all combination techniques from a maximum k 
value (k=0.972) obtained between FASTest LEISH® and ELISA UNIZAR and the minimum k value (k=0.841) obtained 
between MegaELISA LEISH® and MegaFLUO LEISH®, being the global results included in Table 3.
Table 3. Agreement between serological techniques included in the study including Kappa statistic, Standard Error and 95% 
confidence intervals (CI).
Agreement between techniques Kappa statistic
Standard 
Error 95% CI Result
FASTest LEISH®-ELISA UNIZAR 0.972 0.016 (0.941-1.000) Almost perfect agreement
FASTest LEISH®- MegaFLUO LEISH® 0.916 0.027 (0.862-0.970) Almost perfect agreement
MegaFLUO LEISH® – ELISA UNIZAR 0.907 0.029 (0.850-0.963) Almost perfect agreement
MegaELISA LEISH® - FASTest LEISH® 0.907 0.029 (0.850-0.963) Almost perfect agreement
MegaELISA LEISH® - ELISA UNIZAR 0.897 0.030 (0.838-0.956) Almost perfect agreement
MegaELISA LEISH® – MegaFLUO LEISH® 0.841 0.037 (0.768-0.913) Almost perfect agreement
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Concerning the ability of each test to detect anti-Leishmania infantum antibody (immunoglobulin G) depending 
on the dog population, some differences were observed among the group of dogs from endemic areas, especially 
if seemingly healthy (see Materials and Methods). In the case of seronegative healthy dogs, one sample (1/65, 1.5%) 
was classified as seropositive by FASTest LEISH®, 6 samples (6/65, 9.2%) were classified as seropositive by MegaFLUO 
LEISH® (antibody titer ranging from 1:100 (n=5) to 1:200 (n=1)) and finally MegaELISA LEISH® classified 7 samples 
(7/65, 10.8%) as seropositive and 4 samples (4/65, 6.2%) as inconclusive result. For samples included in clinically-
ill infected dogs, all commercial tests analyzed classified all samples as seropositive: antibody titers ranging from 
1:800 to 1:102,400 by MegaFLUO LEISH® and in the case of MegaELISA LEISH® from 12 to 84 Megacor EU. In the 
case of samples from seropositive asymptomatic infected dogs, two samples (2/24, 8.3%) (90 and 56 EU) were 
classified as seronegative by the three commercial tests: MegaFLUO LEISH® (antibody titer 1:20), FASTest LEISH® 
and MegaELISA LEISH® (1 and 4 Megacor EU). The MegaELISA LEISH® also classified a third sample (1/24, 4.2%) 
(90 EU by ELISA UNIZAR) as inconclusive. In non-endemic samples antibodies to Leishmania were not detected by 
any of the three commercial tests. Finally, in the group of dogs with a serological positive result to other pathogens, 
only FASTest LEISH® was totally specific and no positive results were detected. In contrast, MegaFLUO LEISH® test 
gave a positive result in two samples (2/19, 10.5%) for A. platys (antibody titer of 1:20 and 1:40), MegaELISA LEISH® 
test gave positive result in one sample (1/19, 5.3%) for D. immitis and an inconclusive result in other 6 samples 
(6/19, 31.6%), including 4 samples (4/19, 21.1%) for A. platys (antibody titer of 1:20 (n=1), 1:80 (n=2), 1:160 (n=1)), 
1 sample for E. canis (antibody titer of 1:40) and 1 sample with two co-infections T. gondii (IFAT antibody titer of 
1:160) and N. caninum (IFAT antibody titer of 1:100).
Discussion
The absence of a gold standard technique is a recurrent situation in clinical practice and diagnostic research 
studies including confirmatory techniques for L. infantum infection in dogs (Rodríguez-Cortés et al., 2010), cats 
(Persichetti et al., 2017), ferrets (Giner et al., 2020) and humans (Galluzzi et al., 2018). Although it is usual, the 
application of two or more tests combination based on different principles such as molecular, serological or other 
parasitological techniques when there is no reference standard. Nevertheless, classical validation is based on the 
use of a reference test such as IFAT technique to evaluate the other index test (OIE, 2016). The estimates of Se 
and Sp of the index test are biased because the reference test could have high Se and high Sp but not necessarily 
equal to 100%. This latter bias could be resolved using statistical validation based on latent class models in a 
Bayesian analysis. Despite the large number of articles focused on confirmatory techniques validation for diagnosis 
of leishmaniasis, very few studies using a Bayesian statistical approach have been published in dogs (Adel et al., 
2016), cats (Persichetti et al., 2017) and other animals such as lagomorphs (De la Cruz et al., 2016).
In the study, Se value was equal for MegaFLUO LEISH®, FASTest LEISH® and the ELISA UNIZAR, obtaining 
a Se approximately equal to 99.40%, whilst MegaELISA LEISH® was the commercial test with less sensitivity in 
comparison to the others but its sensitivity was high (98.49%). In contrast, the highest Sp was obtained by the 
FASTest LEISH® (98.43%), in comparison to the quantitative tests: ELISA UNIZAR (97.50%), followed by MegaELISA 
LEISH® and MegaFLUO LEISH® (91.9%).
Various confirmatory methods for evaluating L. infantum infection exist, but their performances differ significantly. 
In vitro parasite cultures are laborious, require special facilities, and are limited to research. In contrast, histology, 
immunohistochemistry, molecular methods and quantitative serological methods are frequently applied in clinical 
practice, but samples often need to be sent to a specialized laboratory to perform these techniques (Miró et al., 2008).
The group of dogs coming from the endemic area was heterogeneously composed by clinically-ill dogs and 
apparently healthy dogs, as it is well known that the diagnosis in clinically-ill subjects is easy to obtain with perfect 
performances by means of any diagnostic test. Among the seropositive asymptomatic infected dogs, some had a 
previous serological diagnosis of positivity for Leishmania, some other did not. In any case, the classification into 
subgroups did not have any weight in the Bayesian evaluation. The apparently healthy seropositive dogs and 
clinically-ill infected dogs had different antibody levels ranging from 30 to 372 EU, according to the ELISA UNIZAR 
and in the case of MegaELISA LEISH® antibody levels ranging from 1 to 84 MEGACOR EU. In both ELISAs the antigen 
used is sonicated promastigote protein. However, small differences between the same serological ELISA technique 
were detected between ELISA UNIZAR and MegaELISA LEISH®. Conversely, antibody titers detected by MegaFLUO 
LEISH® ranged from 1:20 to > 1:12800. The main differences between the ELISA and IFAT techniques are the type 
of antigen used and the technical method performed to obtain the results. For IFAT, the entire parasite is present 
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on the slide, and the evaluation is performed with a fluorescence microscope. In contrast, the ELISA technique 
uses different types of antigens, and the results are obtained by measuring the absorbance with an ELISA plate 
reader. In terms of interpreting the results, IFAT is subjective and depends on the operator’s experience, even 
when two different experienced observers examine the samples. Intrinsic analytical variability of each quantitative 
serological technique may explain the differences between results obtained in the present study. In comparison 
to other studies where ELISA techniques showed better performances compared with in-house IFAT technique, 
in our case the Se and Sp of the MegaFLUO LEISH®, were similar to the other tests analyzed in the present study.
In-clinic tests, cytological examinations and rapid serological tests are the most rapid and cheap methods for 
detecting Leishmania infection in dogs. Microscopic examinations of samples, including bone marrow, lymph nodes, 
skin lesions and body fluids, have been used. Bone marrow and lymph nodes are considered the best samples to 
confirm an infection, but microscopy may not be as sensitive and is also time consuming due to the low numbers 
and randomly distributed parasites (Saridomichelakis et al., 2005; Moreira et al., 2007).
In Europe, there are a limited number of commercially available ICTs for CanL with diagnostic performance 
published such as SNAP® Canine Leishmania Antibody Test, Speed Leish K®, INGEZIM® LEISHMACROM and 
WITNESS® Leishmania (Rodríguez-Cortés et al., 2010). Diagnostic performance of ICTs shows high specificity and 
variable sensitivity from low to moderate degree depending on the test evaluated. In our study, the Sp of FASTest 
LEISH® was slightly lower (98.4%) compared to the Sp (100.0%) of other ICTs. On the other hand, the Se of FASTest 
LEISH® was clearly higher in comparison to other tests such as WITNESS® Leishmania with a low Se (58.0%) or 
INGEZIM® LEISHMACROM with a moderate Se (75.0%). Nevertheless, the absence of a common framework makes 
a correct comparison difficult in relation to the standardization of performance between ICTs.
When a test is available to use in a clinical setting, scientific information that is not obtained from the manufacturer 
should be collected. A recent study provided additional information about diagnostic measures of other rapid 
tests that was not included in the technical details (Solano-Gallego et al., 2014). The study (Solano-Gallego et al., 
2014) showed important variations in the Se parameter between the technical set up and the rapid test results. 
A Se of 63.6% was obtained for the Speed Leish K® test, which was not consistent with the higher Se indicated in 
the manufacturer’s instructions. However, the test performance of FASTest LEISH® obtained in the present study 
was similar to previously reported diagnostic performance results supplied with the kit.
Differences in diagnostic performance are described between quantitative serological tests and ICTs evaluated 
simultaneously with a better performance in favour of quantitative serological tests. In this study, Se and Sp were 
similar between FASTest LEISH® and the ELISA UNIZAR used but this situation was not similar in comparison to the 
Sp value detected between FASTest LEISH® (0.984) and the two quantitative commercial tests (0.919). This FASTest 
LEISH® may be a valid alternative in the absence of a quantitative test as a screening test.
One of the great difficulties in the evaluation of diagnostic tests is the lack of standardization of the clinical 
classification of the animal with respect to L. infantum infection. Different classifications and stages of disease have 
been proposed in CanL. However, there are notable differences when it comes to how a dog is classified following 
one or another clinical classification. This added difficulty still complicates the definition of sample selection and 
the possible bias can be established (Meléndez-Lazo et al., 2018). In the present study the Bayesian method, based 
on groups selected only on the basis of endemic/not endemic area, avoided this possible bias.
Sample selection should be included representative and different stage of infection status regarding Leishmania 
infection that can be found when serological tests are evaluated for detecting L. infantum infection. In our study, 
all three serological tests discriminate samples provided from clinically-ill infected dogs and samples from non-
endemic areas. The main problem from the point of view of the application of serological techniques in a clinical 
context is the Se of the serology is lowest early in Leishmania infection but high with progressive infection, and 
this situation is not always included in the evaluation of serological techniques making it crucial that this type of 
samples should be tested. In our study, for a better characterization of this type of dog, an additional confirmatory 
technique including a quantitative PCR in blood was performed. Although blood is not the best samples selection 
for detecting parasitic DNA in comparison to bone marrow or lymph node samples, the procedure to obtain these 
two different samples is painful and difficult to be accepted by the owner when the dog is apparently healthy 
without clinical signs and laboratory alterations.
A potential limitation of similar studies could be associated with the evaluation of the cross reactivity phenomenon 
that it is described commonly in serological techniques (Krawczak et al., 2015). We have evaluated an entire gamma 
of serum samples with a serological positive result to most frequent pathogens present in our geographical area. 
The inclusion of serum samples positive to other type of Leishmania species or Trypanosoma cruzi would be desirable 
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but our region like other regions of the European Mediterranean basin, L. infantum is the common parasite and 
these geographical regions are free of T. cruzi. The analysis of serum samples from different regions where other 
pathogens are present can confirm the potential use of these commercial in other regions aside from Europe. 
In any case, as above clarified, in this study the Bayesian approach overtakes the meaning of the real status of 
every single sample, having the only goal to estimate the performances of the tests.
Conclusions
Latent class analysis provides a useable alternative to traditional test evaluations for serological tests for 
L. infantum infection in dogs, overtaking the needing of a gold standard test or samples with a known serological 
status. Using LCA we have estimated the sensitivity and specificity of the three different serological tests used in 
the European Mediterranean area to detect anti-Leishmania antibodies. The results of present study indicate that 
the immunochromatographic rapid test evaluated FASTest LEISH® shows similar levels of sensitivity and specificity 
to the quantitative commercial tests included.
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